Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRVI Trevi Therapeutics, Inc.

Market Closed 10-09 16:00:00 EDT

13.19

+0.37

+2.85%

盘后13.19

+0.000.00%

19:30 EDT

High13.30	Low12.52	Vol5.03M
Open13.09	D1 Closing12.83	Amplitude6.12%
Mkt Cap1.87B	Tradable Cap1.56B	Total Shares142.00M
T/O66.16M	T/O Rate4.26%	Tradable Shares118.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRVI","market":"US","secType":"STK","nameCN":"Trevi Therapeutics, Inc.","latestPrice":13.19,"timestamp":1791576000000,"preClose":12.825,"halted":0,"volume":5029875,"hourTrading":{"tag":"盘后","latestPrice":13.19,"preClose":13.19,"latestTime":"19:30 EDT","volume":3190641,"amount":42084557.55,"timestamp":1791588605705,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.028460038986354793,"floatShares":118000000,"shares":142000000,"eps":-0.351799,"marketStatus":"Market Closed","change":0.365,"latestTime":"10-09 16:00:00 EDT","open":13.09,"high":13.3,"low":12.5157,"amount":66162729.286125,"amplitude":0.061154,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.351799,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1557201600000,"exchange":"NASDAQ","adjPreClose":12.825,"preHourTrading":{"tag":"盘前","latestPrice":13.09,"preClose":12.825,"latestTime":"09:29 EDT","volume":485,"amount":6336.449825,"timestamp":1791552599999,"change":0.265,"changeRate":0.020663,"amplitude":0.003899},"postHourTrading":{"tag":"盘后","latestPrice":13.19,"preClose":13.19,"latestTime":"19:30 EDT","volume":3190641,"amount":42084557.55,"timestamp":1791588605705,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.225690039263047,"impliedVol":0.5792,"impliedVolPercentile":0.6773},"requestUrl":"/m/hq/s/TRVI","defaultTab":"news","newsList":[{"id":"2670429188","title":"Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670429188","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670429188?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:51","pubTimestamp":1790358664,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics'  upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.Oppenheimer has an outperform rating on the stock, with a price target of $25.Price: 14.40, Change: -0.28, Percent Change: -1.87","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRVI","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669416703","title":"Trevi Therapeutics (TRVI) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669416703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669416703?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:56","pubTimestamp":1790013419,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Trevi Therapeutics, with a price target of $24.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/trevi-therapeutics-trvi-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/trevi-therapeutics-trvi-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668992048","title":"Trevi Therapeutics Director Michael Thomas Heffernan Disposes of USD 595,329 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992048","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668992048?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:55","pubTimestamp":1789678558,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics director Michael Thomas Heffernan disposes of USD 595,329 in common sharesTrevi Therapeutics director Michael Thomas Heffernan cut his direct common stock stake to 6,351 shares on S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLPQBDn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Trevi Therapeutics Director Michael Thomas Heffernan Disposes of USD 595,329 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715937","title":"Trevi Therapeutics to Present Phase 2b CORAL Nalbuphine ER Quality-of-Life Data in IPF Cough at ERS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715937","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715937?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:31","pubTimestamp":1787743869,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER quality-of-life data in IPF cough at ERS 2026Trevi Therapeutics set two ERS Congress 2026 presentations for September 7 in Barcelona on nalbu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1tPNG7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","TRVI","IE00BQXX3C00.GBP","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","BCDF","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4007","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","IE00BQXX3F31.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659211048","title":"Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2659211048","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659211048?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:26","pubTimestamp":1786699601,"startTime":"0","endTime":"0","summary":"In August 2026, Trevi Therapeutics, Inc. reported second quarter and first half results showing higher net losses year-on-year, alongside a wider basic loss per share from continuing operations.\nOn the same day, the company filed a US$149.2 million shelf registration for 8,000,000 common shares, including an ESOP related component, signaling potential future capital raising and employee ownership initiatives.\nWe will now examine how Trevi's wider quarterly loss and new US$149.2 million shelf...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/does-wider-losses-and-new-us1492m-shelf-offering-change-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/does-wider-losses-and-new-us1492m-shelf-offering-change-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626191","title":"Trevi Therapeutics (TRVI) Starts Key Cough Trials, Is It Still 29% Below Fair Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626191","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626191?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:29","pubTimestamp":1786134544,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) has entered a new phase in its development story by kicking off Phase 3 and Phase 2B chronic cough trials while operating with a sizeable cash position that supports ongoing work and potential FDA review.\nSee our latest analysis for Trevi Therapeutics.\nThe latest trial updates and earnings release have come alongside a share price of $18.50, with a 90 day share price return of 27.59% and a year to date share price return of 55.59%. Over the longer term, total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/trevi-therapeutics-trvi-starts-key-cough-trials-is-it-still","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/trevi-therapeutics-trvi-starts-key-cough-trials-is-it-still","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657464519","title":"Trevi Therapeutics, Inc. : Oppenheimer Raises Target Price to $25 from $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2657464519","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657464519?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:34","pubTimestamp":1786106044,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nAZN4TCM2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648520","title":"Trevi Therapeutics, Inc. : Raymond James Raises Target Price to $40 from $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648520?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:31","pubTimestamp":1786102296,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4441F4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657766668","title":"Trevi Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657766668","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657766668?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:40","pubTimestamp":1786052431,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryTrevi Therapeutics, Inc.TRVI.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657646657","title":"Trevi Therapeutics Q2 Net Income USD -17.797 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657646657","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657646657?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:06","pubTimestamp":1786046768,"startTime":"0","endTime":"0","summary":"BRIEF-Trevi Therapeutics Q2 Net Income USD -17.797 MillionAug 06 (Reuters) - Trevi Therapeutics Q2 income from operations USD -20.509 million.Q2 pretax profit USD -17.816 millionQ2 operating expenses USD 20.509 millionQ2 EPS USD -0.11","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXMZVQG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657555657","title":"Trevi Therapeutics Q2 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2657555657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657555657?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046710,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXMZVQG0:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655995385","title":"Trevi Therapeutics Updates Financial Calendar with Upcoming Quarterly Results Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2655995385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655995385?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:17","pubTimestamp":1785442646,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics updates financial calendar with upcoming quarterly results callTrevi Therapeutics schedules a conference call with webcast on Aug. 6, 2026 at 4:30 p.m. ET to review Q2 2026 results,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL6YWp72:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","SG9999014005.SGD","BK4585","BK4588","BK4007","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","NDAQ","LU2095319765.USD","IE00BN0W2W23.USD","BCDF","BK4112","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655538394","title":"Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655538394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655538394?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:05","pubTimestamp":1785441904,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA9CKZYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653951627","title":"Serina Therapeutics Appoints Trevi CCO Farrell Simon to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2653951627","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653951627?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:39","pubTimestamp":1784752762,"startTime":"0","endTime":"0","summary":"Serina Therapeutics appoints Trevi CCO Farrell Simon to boardSerina Therapeutics named Farrell Simon to its board, effective immediately.Simon will join the audit committee, plus the compensation comm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL7FCXjv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2W23.USD","NDAQ","SER","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","TRVI","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","IE00BN0W2T93.GBP","BK4588","BK4112","SG9999014013.SGD","BK4007","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218515","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Erasca (ERAS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218515","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218515?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:31","pubTimestamp":1784547114,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Trevi Therapeutics (TRVI), Amneal Pharmaceuticals (AMRX) and Eras...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-trevi-therapeutics-trvi-amneal-pharmaceuticals-amrx-and-erasca-eras-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-trevi-therapeutics-trvi-amneal-pharmaceuticals-amrx-and-erasca-eras-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRVI","ERAS","XLV","LABU","HCSG","BK4007","XBI","BK4585","BK4581","LU0128526141.USD","BK4539","BK4139","BK4137","BK4588","AMRX","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294462","title":"Trevi Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $24 from $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294462","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652294462?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:02","pubTimestamp":1784541728,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nAZN4T8VGO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652814292","title":"Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Brookdale Senior Living (BKD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652814292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652814292?lang=en_us&edition=fundamental","pubTime":"2026-07-17 23:10","pubTimestamp":1784301009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevi Therapeutics (TRVI) and Brookdale Senior Livin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-trevi-therapeutics-trvi-brookdale-senior-living-bkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-trevi-therapeutics-trvi-brookdale-senior-living-bkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0842063009.USD","XLV","LABU","BKD","BK4581","LU2190626999.HKD","LU0029874061.USD","BK4585","BK4588","HCSG","LU1499592464.USD","BK4007","LU0128526141.USD","XBI","BK4185","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652289397","title":"Trevi Therapeutics rises 10.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652289397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652289397?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:00","pubTimestamp":1784296812,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) is up 10.4%, or $1.80 to $19.16. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-rises-10-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-rises-10-4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","TRVI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644439777","title":"Trevi Therapeutics management attends BIO International Convention in June and July events","url":"https://stock-news.laohu8.com/highlight/detail?id=2644439777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644439777?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:30","pubTimestamp":1781695856,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics management plans to attend the BIO International Convention on June 22-25, 2026 in San Diego.The company is also scheduled for the Leerink Partners Therapeutics Forum on July 14-15, 2026 in Boston.Trevi is set to attend the ERS Cough Conference on July 15-17, 2026 in London.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL3pnHTc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","TRVI","IE00BN0W2W23.USD","BK4588","LU0314104364.USD","BK4585","MNSH","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4007","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162306","title":"Trevi Therapeutics shareholders approve increase in authorized common shares to 400 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162306","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162306?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:08","pubTimestamp":1780603722,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics held its annual shareholder meeting on June 3, 2026.Investors adopted an amended and restated 2019 stock incentive plan, lifting the share reserve by 8 million shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL1NZMVs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trevitherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0518},{"period":"1month","weight":-0.2073},{"period":"3month","weight":-0.2607},{"period":"6month","weight":0},{"period":"1year","weight":0.3296},{"period":"ytd","weight":0.0535}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.062028},{"month":2,"riseRate":0.857143,"avgChangeRate":0.194268},{"month":3,"riseRate":0.571429,"avgChangeRate":0.340057},{"month":4,"riseRate":0.571429,"avgChangeRate":0.129333},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.1063},{"month":6,"riseRate":0.75,"avgChangeRate":0.224365},{"month":7,"riseRate":0.375,"avgChangeRate":-0.014338},{"month":8,"riseRate":0.125,"avgChangeRate":-0.079916},{"month":9,"riseRate":0.25,"avgChangeRate":-0.074732},{"month":10,"riseRate":0.25,"avgChangeRate":-0.065848},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.046063},{"month":12,"riseRate":0.571429,"avgChangeRate":0.034671}],"exchange":"NASDAQ","name":"Trevi Therapeutics, Inc.","nameEN":"Trevi Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Trevi Therapeutics, Inc.,TRVI,Trevi Therapeutics, Inc.股票,Trevi Therapeutics, Inc.股票老虎,Trevi Therapeutics, Inc.股票老虎国际,Trevi Therapeutics, Inc.行情,Trevi Therapeutics, Inc.股票行情,Trevi Therapeutics, Inc.股价,Trevi Therapeutics, Inc.股市,Trevi Therapeutics, Inc.股票价格,Trevi Therapeutics, Inc.股票交易,Trevi Therapeutics, Inc.股票购买,Trevi Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}